Renal effects of canagliflozin in patients with Type 2 diabetes

被引：0
|
作者：
Wong, Yip Fong [1 ]
Shao, Yanli [1 ]
Sum, Chee Fang [1 ]
机构：
[1] Khoo Teck Puat Hosp, Ctr Diabet, Singapore, Singapore
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2016年 / 120卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PD-90
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [41] Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    Desai, Mehul
    Yavin, Yshai
    Balis, Dainius
    Sun, Don
    Xie, John
    Canovatchel, William
    Rosenthal, Norm
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 897 - 900
  • [42] Effect of canagliflozin on liver function tests in patients with type 2 diabetes
    Leiter, L. A.
    Forst, T.
    Polidori, D.
    Balis, D. A.
    Xie, J.
    Sha, S.
    DIABETES & METABOLISM, 2016, 42 (01) : 25 - 32
  • [43] Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Plosker, Greg L.
    DRUGS, 2014, 74 (07) : 807 - 824
  • [44] EFFICACY AND SAFETY OF CANAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS OF DIFFERENT ETHNICITY
    Davidson, Jaime A.
    Aguilar, Richard
    Lavalle Gonzalez, Fernando J.
    Trujillo, Angelina
    Alba, Maria
    Vijapurkar, Ujjwala
    Meininger, Gary
    ETHNICITY & DISEASE, 2016, 26 (02) : 221 - 228
  • [45] Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Greg L. Plosker
    Drugs, 2014, 74 : 807 - 824
  • [46] Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Yaribeygi, Habib
    Maleki, Mina
    Sathyapalan, Thozhukat
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2850 - 2863
  • [47] Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
    Yagi, Shusuke
    Hirata, Yukina
    Ise, Takayuki
    Kusunose, Kenya
    Yamada, Hirotsugu
    Fukuda, Daiju
    Salim, Hotimah Masdan
    Maimaituxun, Gulinu
    Nishio, Susumu
    Takagawa, Yuriko
    Hama, Saori
    Matsuura, Tomomi
    Yamaguchi, Koji
    Tobiume, Takeshi
    Soeki, Takeshi
    Wakatsuki, Tetsuzo
    Aihara, Ken-ichi
    Akaike, Masashi
    Shimabukuro, Michio
    Sata, Masataka
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [48] Canagliflozin and cardiovascular outcomes in Type 2 diabetes
    Sarraju, Ashish
    Spencer-Bonilla, Gabriela
    Rodriguez, Fatima
    Mahaffey, Kenneth W.
    FUTURE CARDIOLOGY, 2020, 17 (01) : 39 - 48
  • [49] Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
    Blonde, Lawrence
    Stenlof, Kaj
    Fung, Albert
    Xie, John
    Canovatchel, William
    Meininger, Gary
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 371 - 380
  • [50] Effects of Canagliflozin in Patients With Type 2 Diabetes and Chronic Heart Failure: A Randomized Clinical Trial (CANDLE)
    Tanaka, Atsushi
    Hisauchi, Itaru
    Taguchi, Isao
    Sezai, Akira
    Toyoda, Shigeru
    Sata, Masataka
    Ueda, Shinichiro
    Oyama, Jun-ichi
    Kitakaze, Masafumi
    Murohara, Toyoaki
    Node, Koichi
    CIRCULATION, 2019, 140
12345